Bristol-Myers Squibb has told the Delhi high court that BDR Pharma’s application for compulsory licence of a generic version of cancer drug, dasatinib, has been rejected, as reported The Times of India.
However, BDR Pharma’s license application is still pending with the Patent Controller, a company official said.
Bristol-Myers Squibb is believed to be «misleading» the court which may «influence the final order," according to a lawyer who represents BDR Pharma.
